AnaptysBio, Inc. reported its financial results for the three months and transitional fiscal year ended June 30, 2026. The company announced that global net sales of its drug Jemperli, managed in collaboration with GSK, reached $644 million for the six months ended June 30, 2026, representing 34% year-over-year growth. During the same period, GSK reported $331 million in global net sales for the quarter, a 26% increase from the prior year.
Regarding its financial position, AnaptysBio reported a net income of $183.9 million for the six months ended June 30, 2026, or $4.52 per share. The company noted that the separation of its subsidiary First Tracks Biotherapeutics was completed on April 20, 2026, and that AnaptysBio reclassified historical assets and liabilities related to that entity as discontinued operations. As of June 30, 2026, the company held $164.1 million in cash, cash equivalents, and investments.
The company provided updates on its key drug candidates and legal matters. AnaptysBio anticipates achieving annualized Jemperli royalties of over $390 million by 2029, based on GSK’s peak monotherapy sales guidance of over $2.7 billion. The company also noted that it expects to pay down the remaining $299 million of its non-recourse debt to Sagard in the second half of 2027.
In regulatory news, the FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of February 2027 for Jemperli in the monotherapy treatment of dMMR/MSI-H neoadjuvant rectal cancer. The company received a National Priority Voucher in November 2025, which may allow for expedited review of this application. Additionally, the FDA has set a target action date of December 12, 2026, for Quimilza (imsidolimab) in the treatment of generalized pustular psoriasis.
AnaptysBio is currently engaged in litigation with GSK and Tesaro regarding Jemperli. A trial was held in July 2026, and a post-trial hearing is scheduled for October 20, 2026. The company anticipates a judgement in the fourth quarter of 2026 or the first quarter of 2027.
